Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 31;7(5):541-548.
doi: 10.1093/nop/npaa011. eCollection 2020 Oct.

Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review

Lisa R Rogers  1 , Quinn T Ostrom  2 , Julia Schroer  3 , Jaime Vengoechea  4 , Li Li  3 , Stanton Gerson  3 , Charles J Nock  3   5 , Mitchell Machtay  3   6 , Warren Selman  1   3 , Simon Lo  7 , Andrew E Sloan  1   3   8 , Jill S Barnholtz-Sloan  3   9
Affiliations

Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review

Lisa R Rogers et al. Neurooncol Pract. .

Abstract

Background: Metabolic syndrome is identified as a risk factor for the development of several systemic cancers, but its frequency among patients with glioblastoma and its association with clinical outcomes have yet to be determined. The aim of this study was to investigate metabolic syndrome as a risk factor for and affecting survival in glioblastoma patients.

Methods: A retrospective cohort study, consisting of patients with diagnoses at a single institution between 2007 and 2013, was conducted. Clinical records were reviewed, and clinical and laboratory data pertaining to 5 metabolic criteria were extrapolated. Overall survival was determined by time from initial surgical diagnosis to date of death or last follow-up.

Results: The frequency of metabolic syndrome among patients diagnosed with glioblastoma was slightly greater than the frequency of metabolic syndrome among the general population. Within a subset of patients (n = 91) receiving the full schedule of concurrent radiation and temozolomide and adjuvant temozolomide, median overall survival was significantly shorter for patients with metabolic syndrome compared with those without. In addition, the presence of all 5 elements of the metabolic syndrome resulted in significantly decreased median survival in these patients.

Conclusions: We identified the metabolic syndrome at a slightly higher frequency in patients with diagnosed glioblastoma compared with the general population. In addition, metabolic syndrome with each of its individual components is associated with an overall worse prognosis in patients receiving the standard schedule of radiation and temozolomide after adjustment for age.

Keywords: glioblastoma; hyperglycemia; metabolic syndrome; obesity; survival.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival time based upon MetS status. Kaplan–Meier curve stratified by MetS status depicts that OS time, in months, did not vary significantly based upon MetS status (median OS for patients with MetS = 7.7 mo, 95% CI: 5.9–12.4, vs median OS in patients without MetS = 12.7 mo, 95% CI: 10.8–16.9, log rank P = 0.22).
Fig. 2
Fig. 2
Age-adjusted survival status for patients receiving concurrent radiation and temozolomide (N = 91). A Kaplan–Meier curve stratified by MetS status and adjusted for age at diagnosis depicts OS status, in months, for patients receiving concurrent radiation and temozolomide and adjuvant temozolomide. Patients with MetS had a significantly shorter median OS (12.4 mo, 95% CI: 9.5–14.2) compared with patients without MetS (17.9 mo, 95% CI: 15.0–22.1, P = 0.18).
See this image and copyright information in PMC

References

    1. Alberti KG, Eckel RH, Grundy SM, et al. ; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. - PubMed
    1. Healy LA, Ryan AM, Carroll P, et al. . Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 2010;22(4):281–288. - PubMed
    1. Irwin ML, Duggan C, Wang CY, et al. . Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011;29(1):47–53. - PMC - PubMed
    1. Bhindi B, Locke J, Alibhai SMH, et al. . Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67(1):64–70. - PubMed
    1. Berrino F, Villarini A, Traina A, et al. . Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat. 2014;147(1):159–165. - PubMed